Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis Woos Payers With Data Showing Entresto Earns Its Keep

Executive Summary

With Entresto sales slowly climbing to $53m in third quarter, Novartis releases data supporting value of heart failure drug in preventing costly hospitalizations at the annual American Heart Association meeting.


Related Content

CAR-T Commercialization Strategies: Views From Novartis And Kite
Enbrel's First Outcomes Contract Is With Harvard Pilgrim; Others May Follow
J&J Outlines Pricing Transparency Plan, Will Others Follow?
Amgen’s Biggest Seller Enbrel Hit By Pricing Pressures, Competition
Novartis Chief: Good Things Come To Those Who Wait
Amgen, Cytokinetics Checked With Payers Before Taking Omecamtiv Into Phase III
Aetna: Entresto’s Label Enabled Outcome-Based Risk Share
Entresto US Sales Barriers Set To Be Removed By Strong Guidance
Novartis Accentuates The Positives Of Heart Failure Drug Entresto At ACC


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts